Ignite Creation Date:
2025-12-25 @ 2:17 AM
Ignite Modification Date:
2026-03-01 @ 10:01 AM
Study NCT ID:
NCT01902160
Status:
COMPLETED
Last Update Posted:
2015-11-09
First Post:
2013-07-15
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Temsirolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
Sponsor:
National Cancer Institute (NCI)
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Recurrent Adult Hodgkin Lymphoma | View |
Keywords: